肌干涉和肌缩性侧面硬化症的认知特征:对347名患者进行的回顾性研究
Edoardo Nicolò Aiello1, Federica Solca1, Silvia Torre1
1Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Frontiers in aging neuroscience
|August 7, 2023
概括
在肌缩侧面硬化症 (ALS) 中,肌干部的参与可能预测执行功能障碍. 凸骨干涉的严重程度与非痴呆性ALS患者的记忆缺陷有关.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 临床医学 临床医学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病.
- 认知障碍 (CI) 是ALS的一个常见的非运动症状.
- 凸骨干涉 (BI) 在ALS中CI中的作用需要进一步澄清.
研究的目的:
- 在非痴呆性骨髓缩侧硬化症 (ALS) 患者中,调查筋干涉 (BI) 作为认知障碍 (CI) 的危险因素.
- 确定BI与认知缺陷相关的特定特征.
主要方法:
- 追溯分析了347名非痴呆性ALS患者的数据.
- 使用爱丁堡认知和行为ALS屏幕 (ECAS) 评估认知功能.
- 由发病,测试分数 (ALSFRS-R-Bulbar),脱节症,严重程度和进展率特征的腹筋干扰;用于识别认知表现预测因子的后勤回归.
主要成果:
- 在ECAS-ALS特定和ECAS-Executive Functioning分尺度上,在测试中巴参与预测了表现受损.
- 较低的ALSFRS-R-Bulbar分数 (表明严重程度更高) 与ECAS-Memory子表现受损有关.
- 在BI在发病时和认知表现之间没有发现显著的关联.
结论:
- 凸骨干涉本身,而不是其在发病时的存在或特定特征,可能是ALS执行功能障碍的选择性风险因素.
- 凸骨干涉的严重程度与非痴呆性ALS患者的记忆缺陷有关.
相关概念视频
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Parkinson's Disease: Overview
598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598


